Insomnia is a common clinical problem. It can be comorbid with other psychiatric disorders such as major depressive disorder（ MDD） and anxiety disorder（ AD）， which leads to hard definition of causality between insomnia and MDD/AD. In view of the mutual relationship between insomnia and MDD/ AD， Comprehensive intervention of both insomnia and MDD/AD has become a new trend. Trazodone， an antidepressant with sedative and hypnotic effects， is widely used in management of insomnia， depression and anxiety. In order to standardize the clinical practice of trazodone in treatment of insomnia， the experts committee of comorbid insomnia reviewed recent evidence and recommendations of guildelines， summarized the pharmacokinetics data， pharmacological effects and clinical applications of trazodone. After repeated discussions by the committee， the consensus was finally completed， which can provide useful clinical suggestion to physicians.